Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202605047 Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS). New Drug Phase Ⅲ
N202605072 Clinical Evaluation of an Artificial Intelligence–Based Stroke Interpretation System (StroCare Suite) in Acute Stroke Management New Medical Device NA
N202605085 A Phase II, Double-blind study to evaluate the efficacy and safety of BB-101 (rhNEGF) for the treatment of atrophic acne scars after laser surgery New Drug Phase Ⅱ
N202605105 A randomized, open-label (unblinding), crossover bioequivalence study to compare two voriconazole oral suspensions in healthy subjects under fasted state. New Drug NA
N202605107 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold) New Drug Phase Ⅲ
N202605135 A Large Language Model–Driven Daily Conversation Cognitive Interaction Platform: Feasibility and Preliminary Efficacy in Older Adults at High Risk of Dementia New Medical Device NA
N202605145 Prospective validation of an AI+ECG screening tool for sudden cardiac death New Medical Device NA
N202605147 A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT) New Drug Phase Ⅱ
N202605152 Translational Development of Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) for Malignant Pleural Disease: A Pleural Fluid Biomarker Platform and a Phase I–II Bridging Pilot New Medical Technology NA
N202606003 A randomized, open-label (unblinding), parallel phase I study to compare the pharmacokinetic profile and safety of tirzepatide 2.5 mg/0.5 mL subcutaneous injection (single dose) with 40 mg and 20 mg tablets (multiple doses) in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
1 2 43 44 45 46 47 48 49 50 51 52 / 52

TOP